関連ニュース

Tenax Therapeutics shareholders were left holding a substantially lower-valued stock after the Phase 3 LEVEL readout for TNX-103 -- and those losses may carry legal rights. NEW YORK, Aug. 12, 2026 /PR

Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or

Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax T